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INTRODUCTION 
Haemophilia is a group of related bleeding disorders that are inherited. 
Our country has the second highest burden of haemophilia patients in the world. 
The pathophysiology of Haemophilia A and Haemophilia B is based on the 
insufficient generation of thrombin by the factor IXa/factor VIIIa complex 
through the intrinsic pathway of the coagulation cascade.
 [1]
 
Spontaneous hemarthroses are characteristic of severe disease. The most 
common sites of bleeding are into joints and muscles. Approximately 80 per 
cent of haemorrhage occurs in the joints, Chronic and recurrent joint bleeds will 
lead to extensive destruction of articular cartilage, synovial hyperplasia and 
other reactive changes. This leads to joint deformity, muscle atrophy and soft 
tissue contractures, eventually leading to functional disability. Severe disability 
due to chronic hemarthroses is a tragic consequence of haemophilia patients in 
India. The onus is on the treating physician to prevent this functional disability 
and hence more light has to be shed into factors leading to joint deformity. 
Functional independence scoring in haemophilia is used to measure the 
disability in haemophilia patients
 [2]
. Identifying the factors having positive or 
negative influence in functional status of haemophilia patients will help to 
improve the quality of life in haemophiliacs and also prolong their survival to 
near normal. 
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AIM OF THE STUDY 
 To assess the functional status of haemophilia patients using 
FUNCTIONAL INDEPENDENCE SCORING IN HEMOPHILIA 
(FISH). 
 
 To assess the factors influencing functional status of haemophilia 
patients. 
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HISTORY OF HEMOPHILIA 
Haemophilia is a sex linked coagulopathy first recognised by Talmud in 
the 5
th
 century. It was then referred to as “haemorrhaphilia” (love of bleeding) 
in 1828.
 [1] 
In 1911, Addis contributed to the history of haemophilia by recognising 
that the defect is correctable with a small amount of normal plasma but he 
incorrectly attributed it to the deficiency of prothrombin. With the advent of 
better protein purification techniques in the 1930s and 1940s, the components of 
thrombokinase were identified. 
In the 19th century several authors recognised the link between bleeding 
episodes to the delayed blood coagulation. Morawitz developed the classical 
theory of coagulation that involved 2 reactions – 
1. Conversion of prothrombin to thrombin by a tissue substance that he named 
as thrombokinase. 
2. Conversion of fibrinogen to fibrin by thrombin.
 [3] 
The defect in haemophilia is attributed to absence of single gene plasma 
protein, which is essential for platelet utilisation and thromboplastin generation, 
was well established by 1947. Pavlovsky
[4]
 identified there are two types of 
haemophilia. Brinkhous
[5]
 and quick identified haemophilia A is due to factor 
viii deficiency and haemophilia B is because of factor IX deficiency. 
10 
 
EPIDEMIOLOGY 
International incidence of Haemophilia A is found to be 1 in 5000 to 
7000 live male births. It occurs in all ethnic groups
 [6]
.50 to 60% of patients 
have severe haemophilia, 25 to 30% have moderate Haemophilia and 15 to 20% 
have mild haemophilia. 
The annual incidence of Haemophilia A has been estimated at 
approximately 1: 5000 male births. The incidence of Haemophilia B is 
estimated at approximately 1: 30,000 male births
 [6]
. 
The incidence of Haemophilia in India is about 1 in 10000 live male 
births. India is the second largest harbour of haemophilia patients. With the 
present records available number of Haemophilia patients in India is 11586 
while the estimated prevalence is about 50000
[7]
. 
Haemophilia B occurs 1 in every 25000 to 30000 male births. As with 
Haemophilia A, Haemophilia B also occurs in all ethnic groups and geographic 
distributions. 
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EPIDEMIOLOGY IN INDIA 
[14]
: 
 
ETIOLOGY 
Haemophilia A is a heterogeneous disorder resulting from the reduced 
levels of functional factor VIII in the peripheral circulation. This can be due to 
either decreased levels of factor VIII or decreased functionality of factor VIII 
[1]
. 
Factor VIII must be activated by thrombin for it to be an effective cofactor of 
factor IXa. Factor IXa has capacity to activate Factor X is exponentially 
increased in the presence of activated factor VIII - FVIIIa. Thus the clinical 
manifestations of Haemophilia A and B are not very much different from each 
other. Together Factor IXa and VIIIa activate factor X which is necessary for 
effective thrombin formation. In the absence of either factors clot formation is 
delayed and the clot thus formed is easily friable, dislodged and subjected to 
fibrinolysis which leads to excessive bleeding. 
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GENETICS 
[6] 
Haemophilia A and B are X linked recessive disorders. About 30% of 
Haemophilia A mutations can arise de-novo. The gene for Factor VIII is large 
with 26 exons and 25 intervening introns. This makes identification of the 
mutation difficult. 
All the sons of affected haemophiliac males are normal while all the 
daughters are obligatory carriers. Sons of carriers have 50% chance of being 
affected and the daughters of the carriers have a 50% chance of being carriers 
themselves. In female carriers, because of lyonization there might be 
preferential expression of the defective haemophilic allele. Such females who 
have Haemophilia are called “lyonized carriers”. Other mechanisms for female 
Haemophilia include homozygosity for the defective Factor VIII allele and 
hemizygosity for the defective gene.  
No single mutation can cause Haemophilia. Hundreds of deletions, point 
mutations and inversions have been identified. 
Analysis of Factor IX mutations show that it occurs due to endogenous 
processes – deamination of CpG dinucleotides rather than from environmental 
effects. As with Haemophilia A, no single gene has been attributed to the 
development of Haemophilia B. 
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FACTOR VIII gene and HAEMOPHILIA: 
Factor VIII gene contains 186 kb with 26 exons, and produces an mRNA 
transcript of 9kb which is translated into 2351 amino acid polypeptide. The 
mature protein is divided into homologous domains named A1, A2, B, A3, C1, 
C3.The most common defect is inversion of 500-600 kb region that results in 
disruption of F8 region of intron 22. Additional inversion of Intron 1 of Factor 
VIII contributes to 5% of severe Haemophilia 
[12]
.  Point mutations involving 
CpG dinucleotide are more common. 
 
FACTOR IX GENE AND HEMOPHILIA B 
[28]
: 
The gene for factor IX is located on the long arm of chromosome X. It is 
much smaller than the gene for factor VIII measuring only around 33kb. 
F9 is the gene’s official symbol. The F9 gene is located on the long (q) arm of 
the X chromosome between positions 27.1 and 27.2.
[12] 
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GENETICS IN HEMOPHILIA  
When a carrier woman marries a normal man, there is a 50% chance of 
the girl Children to be carriers and 50% chance of her son to be a Haemophilic. 
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VASCULAR CONSTRICTION 
After a trauma, the blood vessel immediately constricts causing reduced 
blood leakage. This occurs due to local myogenic reflex, local autocoid factors 
released by the vessel wall and the platelets and neurogenic reflex. The 
neurogenic reflex originates from the pain nerve endings. Of the above 
mentioned factors, the myogenic reflex is the most powerful. Of the autocoids, 
the most important vasoconstrictor is the thromboxane A2. 
PLATELET ACTIVATION 
If the cut vessel is very small, it can be sealed by the platelet plug itself. 
Many such small leaks keep happening throughout the day. 
17 
 
PLATELET PHYSIOLOGY 
The platelets’ cell membrane has glycoprotein that repulses attachment to 
the vessel wall but gets attached to injured endothelium and exposed collagen. 
In addition platelets contain phospholipids that activate various stages of blood 
coagulation process. The half-life of platelets is 8 to 12 days. 
When the platelets come in contact with collagen they change their 
characteristics. They tend to swell up and the contractile process within the 
platelets releases the contents of the granules. These make the platelets even 
stickier and they tend to bind avidly to each other and to the exposed collagen 
and Von Willebrand factor. It also releases ADP which forms Thromboxane 
A2. This further makes the platelets sticky. A platelet plug is formed which is 
initially loose and then tends to become closely packed. Small leaks are closed 
by platelet plugs themselves. 
The coagulation process is initiated by three factors 
[1][6]
 
 Damage to bleed vessel 
 Damage to the blood components 
 Exposure of blood to damaged endothelial cells or the underlying collage 
In each instance, it leads to the formation of the prothrombin activator which 
converts prothrombin to thrombin and the coagulation continues 
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The prothrombin activator can be formed by two processes:- 
 EXTRINSIC PATHWAY – Begins with the trauma to the vessel wall 
 INTRINSIC PATHWAY – Begins in the blood itself 
EXTRINSIC PATHWAY
[1]
: 
This is also known as tissue factor pathway. This begins with the 
exposure of blood to the damaged extra vascular tissue or traumatised vessel 
wall. 
STEPS 
1. Release of TISSUE FACTOR: Damaged vessel releases several tissues 
factors or tissue thromboplastin.  
2. FACTOR VII AND TISSUE FACTOR: The lipoprotein tissue factor 
forms complexes with Factor VII and in the presence of Calcium 
catalyses the activation of Factor X to Xa. 
3.  Factor Xa combines with Factor V and in the presence of calcium 
becomes the PROTHROMBIN ACTIVATOR. 
4.  Prothrombin activator complex in the presence of calcium converts 
prothrombin to thrombin and the coagulation continues. 
In the prothrombin activator complex, Factor X is the actual protease and 
Factor V accelerates the protease activity. The formed thrombin further 
activates Factor V which becomes an additional accelerator of prothrombin 
activator thereby becoming a positive feedback mechanism. 
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INTRINSIC PATHWAY
[1]
 
The second pathway for initiating coagulation is the intrinsic pathway 
which gets activate with damage to the blood components. 
1. Trauma to blood causes activation of Factor XII. When Factor XII comes in 
contact with wet able surfaces like collagen it gets activated to a protease – 
Factor XIIa. Simultaneously, platelets release platelet factor 3 which in turn 
contributes to the coagulation cascade. 
2. Factor XIIa activates Factor XI to XIa. This reaction needs High molecular 
weight kininogen and prekallikrein. 
3. The activated Factor XI then enzymatically cleaves Factor IX to form the 
activated Factor IXa. 
4. The activated Factor IXa, along with activated factor VIIIa, Platelet factor 3 
and platelet phospholipids end in activating Factor X to Xa. Factor VIII is also 
known as the antihaemophlic factor. 
5. This step is the same as in intrinsic pathway. The activated Factor X 
combines with Factor V to form the prothrombin activator complex. 
6. The prothrombin activator causes conversion of prothrombin too thrombin 
thereby setting the coagulation cascade into motion. 
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CONVERSION OF PROTHROMIN TO THROMBIN 
After the formation of prothrombin activator by either the intrinsic or 
extrinsic pathway, it causes conversion of prothrombin to thrombin in the 
presence of ionic calcium. Thrombin causes polymerization of fibrin molecules 
within 10 to 15 seconds. So, the rate limiting step in coagulation process is the 
formation of the prothrombin activator and not the steps that happen beyond it. 
Platelets also play a role in the conversion of prothrombin to thrombin as most 
of the prothrombin binds to the prothrombin receptors on the surface of the 
platelets. 
 
PROTHROMBIN AND THROMBIN 
Prothrombin is formed by the liver and it needs Vitamin K for formation. 
The normal plasma concentration is about 15mg/dl. It is constantly being used 
up in the body for coagulation process. In the presence of liver failure or 
vitamin K deficiency, prothrombin production is grossly reduced and can result 
in coagulopathy. Thrombin is the link between vascular injury, coagulation and 
platelet activation. 
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CONVERSION OF FIBRINOGEN TO FIBRIN  
FIBRINOGEN 
Fibrinogen is a high molecular protein, (MW=3, 40,000) with a plasma 
concentration of 100 to 700mg/dl. It is produced in the liver and so liver disease 
can result in reduced plasma levels of fibrinogen. Because of its high molecular 
weight, little, leaks outside the blood vessels. In case of trauma, it leaks out and 
can cause clotting of tissue fluids just like plasma and blood. 
 
CLOT RETRACTION 
Within a few minutes after clot formation, it begins to contract expressing 
the serum. In this way serum differs from plasma because it cannot clot as the 
clotting factors have been depleted. The platelet themselves contribute to the 
process of clot retraction. Clot retraction is affected in case of 
thrombocytopenia. The platelets bring the fibrin molecules together. The 
contractile process within the platelets gets activated and this is involved in clot 
retraction. It also releases procoagulant factors. The contraction is activated by 
thrombin and accelerated by the calcium released from the endoplasmic 
reticulum and Golgi apparatus within the platelets. As the clot retracts, the 
edges of the broken blood vessels are pulled together there by contributing 
further to complete haemostasis. 
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COFACTORS 
Substances required for the proper functioning of the coagulation cascade: 
 CALCIUM 
 VITAMIN K 
Except for the first two steps of the intrinsic pathway, Calcium ions are 
needed for the activation and propagation of the entire coagulation cascade. In 
live, the levels of ionised calcium rarely become low enough to affect the 
coagulation. But after sampling, blood can be maintained in the liquid state by 
adding citrate, that binds with the ionised calcium or oxalate, which precipitates 
the calcium. 
Vitamin K is essential for the gamma carboxylation of Factor II, VII, IX 
and X. This process is essential for the factors to bind to phospholipids and 
there by participate in the coagulation cascade. In the absence of vitamin K, 
either due to deficiency or liver disease, PIVKAs (Proteins formed in the 
absence of Vitamin K) are formed. These are defective proteins and do not 
participate effectively in the coagulation cascade. 
 
REGULATORS
[6]
 
There are four mechanisms that keep platelet activation and the coagulation 
cascade in check. Abnormalities can lead to an increased tendency toward 
thrombosis: 
23 
 
 Protein C  
Thrombin activates protein C into aPC. Activated protein C inhibits 
factor Va and VIIIa. This causes termination of the role of factor VIIIa in 
the tenase complex and the role of factor Va in forming the prothrombin 
activator complex. The net effect on the coagulation cascade is inhibition 
of further fibrin and there by clot formation.  
 Antithrombin is a serine protease that inhibits factor Xa and thrombin. 
Antithrombin deficiency can cause thrombotic disorders 
 Tissue factor pathway inhibitor (TFPI) limits the action of tissue factor 
(TF) and also inhibits excessive TF-mediated activation of Factor VII and 
Factor X 
 Plasmin is produced from the plasminogen, a zymogen produced in the 
liver. Plasminogen after binding to clots it adopts an open conformation 
and can be activated to plasmin by a variety of factors, the most important 
of which is Tissue plasminogen activator. Plasmin deficiency, which is 
rare in humans, can cause thrombosis. 
 
PRENATAL DIAGNOSIS AND CARRIER DETECTION
[11][12]
 
Prenatal diagnosis can be suggested to woman those who are related to 
obligate Haemophilia carriers and known Haemophiliacs. Germ line mutations 
have different implications when it occurs in the grandfather and the mother. 
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Prenatal diagnosis can be done using cells obtained during amniocentesis 
done at 16 weeks of gestation. If the foetus is a female little is the concern as 
carrier females rarely have bleeding manifestations. In case of a male foetus, the 
diagnosis can be made by DNA analysis of the cells.  
Studies identified the causative mutation in 90% of patients with mild and 
moderate haemophilia A but only 50 to 60% of patients with severe disease
[12]
.  
The analysis is performed in the eleventh to twelfth week of gestation either by 
amniocentesis or chorionic villus sampling. 
 
CLINICAL PRESENTATION
[23][24][1] 
Clinical presentation of Haemophilia A and B are indistinguishable. Both are 
very similar in their presentation.  
 Severe Haemophilia refers to factor levels less than 1% of normal or less 
than 0.01u/ml. They present in early infancy with spontaneous 
haemorrhage.  
 Moderate haemophilia has factor levels between 1 to 5% of normal. They 
present with increased bleeding after a minor trauma and surgery. 
Spontaneous bleeds are rare.  
 Mild haemophilia refers to factor levels of 6 to 30% of normal. These 
patients bleed secondary to surgery and rarely do they present with 
spontaneous hemarthroses. 
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 Most carriers have factor levels greater than 50% and do not have 
bleeding manifestations. Factor VIII levels should be checked in all 
Haemophilia carriers. 
 
INTRAPARTUM COMPLICATIONS 
A study of the modes of delivery and peri-natal complications in affected 
male babies shows that the risk of intracranial bleed is less in normal delivery. 
(<3.8%)
[6]
. The risk of subgaleal and cephalic hematoma increases with vacuum 
delivery. Caesarean section does not eliminate the risk of intracranial 
haemorrhage. Forceps delivery and prolonged labour increase the risk of 
intracranial bleeds. Seizures are common during the acute intracranial bleed 
episode. 
Psychomotor complications and cerebral palsy can occur as long term 
complications. In a European study, involving 508 children born with 
Haemophilia A or B, intracranial bleeds occurred in 18 (3.5%) within the first 
28 days of life
 [8]
. 
 
CIRCUMCISION AND BLEEDING 
50% of undiagnosed haemophiliacs have excessive bleeding during 
circumcision that can be stopped with factor infusion. Thus, failure to bleed 
does not eliminate the presence of Haemophilia in that patient. 
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AGE OF BLEED ONSET 
Children with severe haemophilia become symptomatic within the first 2 
years of life. In a study, the mean age of first bleed leading to the diagnosis of 
Haemophilia was at 0.9 years of age, in the absence of any prothrombotic factor 
coinheritance. 
In the presence of prothrombotic factors, the mean age for diagnosis was 
late and was around 1.6 years of age
[5]
. Joint bleeds are very common and early 
diagnosis would help to prevent the joints from hemarthropathy. 
The age of diagnosis in mild and moderate Haemophilia is later than that 
for severe haemophilia.  
Mild haemophilia without family history can go undetected for a very long 
period of time, as about one third of patients have very few bleeding episodes. 
 
 HEMARTHROSES 
 HEMATOMAS 
 PSEUDO TUMORS 
 HEMATURIA 
 NEUROLOGICAL COMPLICATIONS 
 MUCOUS MEMBRANE BLEEDS 
 POST SURGICAL BLEEDS 
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HEMARTHROSES
[1][6]
 
Hemarthroses is the most common bleeding manifestation in severe 
haemophiliacs contributing to about 75% of the bleeding episodes
[30]
. Anatomy 
of the synovium favours bleeding, it has numerous cells and abundant 
capillaries that lie beneath the synovial layer. These capillaries are susceptible 
to damage during mechanical trauma associated with the daily use of joints. The 
joints involved in decreasing order of frequency are knee, elbow, ankle, 
shoulder, elbow and hip. Hinge joints are more commonly affected than ball and 
socket joints. 
Hemarthroses might produce an aura of discomfort that gradually 
progresses to cause joint enlargement and excruciating pain. The joint becomes 
swollen, warm and tender with decreased range of movement. Patient might 
have a mild fever during the bleed. However, sustained fever indicates an 
infected joint. 
When bleeding stops, the blood is reabsorbed in a couple of days. If the 
bleed is treated early and the joint is not affected chronically, pain subsides in 6 
to 8 hours and disappears in 12 to 18 hours. However, repeated bleeding into the 
joint causes articular destruction and leads to haemophilic arthropathy. Once 
chronically affected it may be difficult to distinguish the pain of degenerative 
arthritis from the pain of bleeding. 
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The synovium becomes thickened and folded leading to repeated bleeds 
in the same joint causing the so called target joint. The joints most often 
involved are the weight bearing joints, knee and ankle. Bleeding into a joint 
with thickened synovium causes less pain than bleeding into a normal 
synovium. 
 
In the presence of fever, leukocytosis and other systemic manifestations 
the probability of an infected hemarthroses should be considered. Rapid 
diagnosis is a must as infection in such joint progresses rapidly causing loss of 
joint space and architecture. The joint should be aspirated under strict aseptic 
techniques and factor replacement should be given. Chronic haemophilic 
arthropathy is painful with weight bearing but the pain subsides or disappears 
once the joints become ankylosed. Muscle atrophy around the joint can lead to 
increased inability and increased bleeding from the loss of cushioning effect 
provided by the muscles. Patients with factor VIII or IX deficiency with levels 
greater than 20% of normal rarely develop haemophilic arthropathy even if they 
have experienced previous bleeds
[6]
. 
 
 
 
 
29 
 
Radiographic stages of haemophilic joint
[6]
  
 
Stage 0 – Normal joint 
Stage 1 – fluid in the joint 
Stage 2 – Osteoporosis and epiphyseal overgrowth – Fig A 
Stage 3 – Subchondral bone cysts – Fig B (arrowheads) 
Stage 4 – Prominent bone cysts with marked narrowing of joint space – Fig C 
(arrows) 
Stage 5 – Joint obliteration with epiphyseal overgrowth 
 
HEMATOMAS 
Hematomas can occur in the subcutaneous plane or into the muscle
[6]
. 
They are very characteristic of clotting factor deficiencies. Hematomas, with 
bleeding into the muscles occur most commonly in the quadriceps, iliopsoas and 
forearm. 
 
 
30 
 
RETROPERITONEAL HEMATOMA 
Retroperitoneal hematomas can dissect through the diaphragm into the 
chest and neck and compromise the airways. They might cause ureteral 
obstruction and compromise renal function. An abdominal hematoma can 
rupture and drain into the colon which is very rare and most often fatal. 
Iliopsoas bleeds tend to be large and compromise neurovascular 
structures causing compartment syndrome. These bleeds can be localised with 
ultrasound and require larger doses of factor VIII
[30]
. 
Patients with Haemophilia can develop hematoma of the bowel wall and 
present as appendicitis, intestinal obstruction or intussusception. The diagnosis 
of “pseudo appendicitis” can be made with CT scan. 
 
PSEUDOTUMOR
[30]
 
Pseudotumor is also known as blood cysts. There are three types of 
Pseudotumor
[6]
, 
Type 1: Simple cyst; confined by the tendinous attachment within the fascial 
muscle. 
Type 2: Simple cyst that compromises the vascular supply to the adjacent bone 
and periosteum resulting in bone resorption and cyst formation 
Type 3: Subperiosteal bleeding resulting in separation of the periosteum from 
the bone cortex. 
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Pseudotumors contain either a serosanguinous fluid or brownish material 
surrounded by a fibrous membrane. They cause pain only when the collection is 
rapid or when they compress nearby neurological structures. Pseudotumors tend 
to expand over years together and can become multiloculated. They can reach a 
stage where they become inoperable. Sinus tract formation from a pseudotumor 
is a risk for increased infections. 
Most common sites for pseudotumor formation are in the lower limb but 
they can occur at other sites too. Small joints of the hands can be involved in 
younger patients. 
MRI and CT help in diagnosis. Needle biopsy of the pseudotumor should 
be avoided for fear of bleeding and infection. The only definitive treatment is 
complete excision. If incompletely removed the pseudotumor tends to reform. 
 
HEMATURIA 
Haematuria is frequently seen in severe haemophiliacs. Bleeding can 
occur from anywhere along the genitourinary tract from the renal pelvis till the 
bladder. Patients can experience colicky pain if clots obstruct the ureter. 
Bleedings tends to last from days to weeks depending on the severity of the 
bleed.  
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NEUROLOGICAL COMPLICATIONS
[6]
 
Intracranial bleed is the most severe of all complications. The bleed can 
occur spontaneously but most commonly occurs after a trivial trauma. 
Symptoms might occur soon after the bleed or it might be delayed. Suspicion of 
an ICH should arise when a haemophilia patient complains of severe headache. 
Treatment should be started immediately when there is a suspicion of 
intracranial bleed without waiting for imaging studies. 
Bleeding into the spinal cord is very rare and can result in paraplegia
[31]
. 
Epidural bleeding compressing the cord is more common. Muscle hematomas in 
the periphery can result in peripheral nerve compression. Femoral nerve 
compression by iliopsoas bleed is most common and can result in sensory loss 
over the anterior and lateral thigh, weakness and atrophy of the quadriceps. 
Ulnar nerve is the next most commonly involved peripheral nerve. 
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MUCOUS MEMBRANE BLEEDS 
Mucous membrane bleeds in the form of epistaxis and haemoptysis is 
common in haemophiliacs. Peptic ulcer disease is more common in 
Haemophilia A when compared to the general population. Occult blood loss in 
urine or stools might contribute to the iron deficiency seen in these patients and 
was recorded so in a study conducted in the university of Florida. 
 
POST SURGICAL BLEED 
Severe haemophilic patients need to be treated with factor preoperatively 
and post operatively. Mild or moderately affected patients are at times 
diagnosed only after bleeding occurs from the surgical site. Wound healing is 
poor in such patients. Appropriate Factor VIII replacement can prevent intra 
operative and postoperative bleeding. 
Dental extraction is the most common surgical procedure done on 
haemophilia patients. Loss of permanent teeth causes more bleeding than loss of 
deciduous teeth. 
COMPLICATIONS IN HAEMOPHILIA 
There are three major complications that can occur in haemophiliacs, 
 Joint destruction and abnormalities due to hemarthroses 
 Blood borne infection transmission 
 Development of Inhibitor antibodies 
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HEMOPHLIC ARTHROPATHY
[1]
 
There are several factors that contribute to the development of 
arthropathy. The most important among them would be the deposition of iron in 
the synovium and the development of synovial fibrosis that leads to contracture 
formation. The patient has extreme pain and limitation of the range of 
movement. 
Primary prophylactic treatment with factor VIII or IX dramatically 
reduced the incidence of arthropathy and increased the quality of life. A 
randomized control trial comparing three times per week prophylactic dosing 
against the on-demand dosing showed that prophylactic dosing was superior to 
on-demand dosing schedule. 
The relative risk of MRI detected joint damage with episodic therapy as 
compared with prophylaxis was 6.1 (95% CI 1.5-24)
[34]
. Orthopaedic 
complications still remain a major issue as on-demand treatment is still the 
treatment method followed in India. 
The completed Joint Outcome Study in the United States has 
demonstrated that prophylaxis with Factor VIII at 25-35 units per kilogram 
body weight every other day is superior to intensive on-demand (e.g., 40 
units/kg initially, then 25 units/kg at 24 and 72 hours) factor replacement 
therapy in preventing joint disease in previously pristine joints at age six years. 
The 80 per cent lower incidence of pristine joints in the on-demand arm was 
confirmed by validated physical exam and radiographic scoring as well as by 
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follow-up magnetic resonance imaging of ankles, knees, and elbows in the 66 
children randomly assigned between the two arms of the study. 
 
INFECTION 
The incidence of infection has dramatically reduced with the advent of 
recombinant products and use of intensive donor screening and virucidal 
techniques. Patients treated with older factor VIII or IX concentrates are at 
higher risk of developing Hepatitis B, C and D or HIV infection. Co-infection 
with HCV and HIV has a bad prognosis as far as the liver derangement is 
concerned. These people tend to respond poorly to treatment. Since the mid 
1980s, no HIV infection has been reported with the use of anti-haemophilic 
factor with advanced virucidal techniques. 
Other rare infections that can be transmitted through the use of anti-
haemophilic factors are parvo B19, Creutz feldt Jacob disease and the new 
variant of CJD. CJD and nvCJD are transmissible spongiform encephalopathies. 
 
DEVELOPMENT OF INHIBITORS 
The most important complication of Haemophilia is the development of 
inhibitors to factor VIII or IX. 
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HAEMOPHILIA A AND INHIBITORS 
The development of inhibitors is more common with Haemophilia A than 
B. The severe Haemophilia A phenotype is most commonly due to a null 
mutation. A null mutation refers to the complete absence of the protein thereby 
predisposing to the development of inhibitors. In severe disease 30%, moderate 
disease 3% and in mild disease 0.3% tend to develop inhibitors
[32]
. 
Genetic and environmental factors play a role. The presence of a first 
degree relative with Inhibitors increases the risk of inhibitor development three 
fold in the patient. 
 
 
Mutations that play an important role in inhibitor formation include, 
inversion of intron 22, large deletions affecting more than one domain and 
nonsense mutations involving the light chain.  
Inhibitor development is seen more in patients exposed to continuous 
factor infusions as seen during surgeries
[1]
.  
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Normally when factor VIII is secreted, it is non-covalently bound to vWF 
via the light chain. Upon thrombin activation, factor VIIIa dissociates from 
VWF and via the C2 domain, which is no longer bound by VWF, binds to 
phosphatidylserine on the platelet membrane. Inhibitors interrupt this process 
through a number of different mechanisms. 
With the development of inhibitors, the frequency of bleed does not 
increase but the patient tends to respond poorly to treatment and develop 
damaged joints that bleed more frequently.  
Any Haemophilia patient who fails to respond to treatment should be 
evaluated promptly for the development of inhibitors. 
The diagnosis is made by using the Bethesda assay. It was developed in 
1975 and it depends on the ability of the patient’s plasma to inactivate factor 
VIII in the normal plasma. The result is expressed in Bethesda units
[28]
. 
 
HAEMOPHILIA B AND INHIBITORS 
The incidence of inhibitors in Haemophilia B is less than that in 
Haemophilia A
[1]
. The other differences include the possibility of anaphylactic 
reaction on infusing factor IX concentrates, lesser response to immune tolerance 
therapy and increased incidence of nephrosis with immune tolerance therapy. 
 Similar to Haemophilia A, inhibitors should be suspected when treatment 
failure happens. Treatment is similar to that of Haemophilia A with 
inhibitors
[26]
. 
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DIAGNOSIS AND DETECTION OF CARRIERS 
Diagnosis begins with review of family history especially on the maternal 
side. The mother can be identified as a carrier when a family history of bleeding 
is present. One third of patients have a negative family history. Hence, the lack 
of family history does not rule out haemophilia. 
 
REASONS FOR NO FAMILY HISTORY 
 The patient might have spontaneous mutations involving factor VIII gene. 
25 to 33 % of cases have spontaneous mutations. 
 Neonatal deaths or the passage of the trait through successive female 
carriers might give a negative family history. 
Symptomatic haemophilia is well documented in female. The possible reasons 
include, 
 Unequal and early inactivation of the X chromosome 
 Mating between an affected male and a carrier female produces 
homozygous disease in one half of the female offspring. 
 An abnormal karyotype as in Turner’s syndrome 
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SCREENING TESTS 
Three initial tests should be performed in patients presenting with unknown 
bleeding disorder. 
1. Platelet count 
2. Prothrombin time 
3. Activated partial thromboplastin time 
PROLONGED PT AND OR aPTT 
A normal PT, Platelet count and a prolonged aPTT are characteristic of 
Haemophilia A and Haemophilia B. The test is abnormal in those with factor 
levels less than 30%. In mild diseases the aPTT may be normal. So, in case of a 
mild undiagnosed bleeding disorder with normal lab values factor assays should 
be done. 
Other disorders that prolong the aPTT but not the PT include acquired 
inhibitors to factor VIII and IX. A similar pattern is also seen in patients with 
antiphospholipid antibodies but they tend to thrombose rather than bleed. 
In the absence of inhibitor which does not occur in patients not treated with the 
factor, the elevated aPTT should be correctable with normal plasma. 
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SPECIFIC ASSAYS 
Specific assays for factor deficiency that result in isolated prolonged 
aPTT are done in the order of statistical significance – VIII, IX and XI.  
There are two methods to perform the assay for factor VIII – one stage method 
and two stage method. 
The one stage method is preferred as it easier and cheaper. But there are 
chances of false negatives if only the one stage method was used for diagnosis. 
Chromogenic substrate assay is another method for identifying factor VIII 
levels. The above test depends on the Factor VIII mediated activation of factor 
X. 
Other methods that have developed include, immunoradiometric methods 
and enzyme linked immunoabsorbent assay. 
 
DISTINCTION FROM VON WILLEBRAND DISEASE 
Ristocetin cofactor assay is the most sensitive test to identify Von 
Willebrand disease. It is difficult to perform. Von Willebrand is an acute phase 
reactant and its level increases in times of stress like pregnancy, fever and 
hormone replacement. In type 2N Von Willebrand disease, there is a defect in 
the binding site for factor VIII and bleeding results from the low levels of factor 
VIII. Type 2N Von Willebrand is a diagnostic difficulty. It is one differential 
diagnosis of mild Haemophilia. Type 2N Von Willebrand disease should be 
suspected in any female with a low level of Factor VIII. 
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DIFFERENTIAL DIAGNOSIS 
 Von Willebrand disease 
 Platelet disorders – eg. Glanzman thrombasthenia 
 Clotting factor deficiency – V,VII,X or XI 
 Acquired haemophilia 
Haemophilia is diagnosed with the presence of a positive family history, 
prolonged bleeding, hemarthroses and spontaneous soft tissue bleeds. The last 
two features differentiate it from von Willebrand disease in which hemarthroses 
and soft tissue bleeds are generally rare except in case of severe type 3 disease. 
 The main differentiating factors are a prolonged bleeding time, reduced von 
Willebrand antigen assay and abnormal ristocetin induced platelet aggregation. 
vWd – Normandy variant is difficult to distinguish from Haemophilia A. In the 
Normandy variant, vWd levels are normal but factor VIII levels are low. Factor 
VIII is produced normally but there is a failure in the incorporation of factor 
VIII into the von Willebrand factor. 
Differentiating Haemophilia A and B is impossible from history and physical 
examination. Factor assay is a must. Similarly, factor assays are needed to 
differentiate between Haemophilia and deficiency of other clotting factors. 
Acquired Haemophilia is seen in autoimmune syndromes, in which inhibitors to 
Factor VIII develop spontaneously. 
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TREATMENT 
Treatment of Haemophilia includes 
 Preventive measures 
 Treatment with factor replacement either as on-demand or prophylaxis 
 Treatment of complications 
PREVENTIVE CARE
 
Circumcision 
Approximately 40% of undiagnosed haemophiliacs bleed in association 
with circumcision
[1]
. For this reason, male babies born to female carriers should 
be deferred from the procedure. Whether circumcision can be carried on in this 
group is still a controversy. Fibrin glue can be used. It reduces the bleeding and 
the high cost involved in the treatment of haemophilia. 
Immunisation 
The routine immunizations given intramuscularly in normal people can 
be used. Pressure and ice packs must be applied for three to five minutes at the 
injection site in haemophiliacs. Intramuscular injections are contraindicated in 
Haemophilia. Hepatitis B vaccine should be given to all infants affected with 
Haemophilia. Inactivated polio vaccine should also be given. 
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Dental Care 
Proper dental care should be advocated. The patients should be taught 
about the importance of routine cleaning and maintenance of oral hygiene. Early 
and proper toothbrush training should be given to the children. 
Counselling and Education 
Genetic and Psychosocial counselling should be given to the patient as 
well as the family members. About 30% of the cases have no family history and 
in that case proper education about the disease and its complications is very 
important. Normal socialization and development should be encouraged. 
Exercise and Athletic participation 
A regular exercise regimen should be introduced into the life of 
haemophiliacs. Most of the Haemophilia patients, for fear of bleed, tend to 
become sedentary and end up with obesity which further increases the risk of 
bleeds in the weight bearing joints. With the advent of prophylaxis all over the 
world, The World federation for Haemophilia advocates regular exercise 
regimen. Proper communication between the parent, patient and staff is very 
important. 
REPLACEMENT THERAPY 
The cornerstone to the management of Haemophilia is the factor 
transfusion. The dosing is standard but the length of the treatment; choice of 
product depends on individual decision.  
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Guidelines for replacement have been established but the minimum factor 
level required for haemostasis has not been established. For minor bleeds it’s 
enough if the factor level is raised to 25 to 30% of normal. In case of major 
bleeds the factor levels should be raised to 50% of normal and in life 
threatening bleeds and surgery the factor levels should be maintained at 100%. 
Each unit of Factor VIII per kg of body weight tends to increase the factor level 
by 2%. Therefore, 1750 units of factor VIII will raise the factor level by 50% of 
normal. The decrease in factor level post transfusion depends on the 
pharmacokinetics of the factor. 
Half-life of factor VIII is 8 to 12 hours. Half of the initial dose is repeated 
every eight hours to maintain the desired factor level
[40][1]
. 
Factor VIII can be derived from the plasma or can be recombinant – derived 
from cell lines genetically engineered to express large amounts of factor VIII. 
Solvent treated fresh frozen plasma can be given in the absence of factor.  
 
1
st
 GENERATION RECOMBINANT FACTOR VIII 
These recombinant factors are derived from the cell cultures of 
transfected hamster derived cell lines and need no further purification. The 
human albumin, added for stabilization purposes, contributes to the risk of viral 
contamination. 
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2
nd
 GENERATION RECOMBINANT FACTOR VIII 
This recombinant factor does not contain albumin. Instead, sucrose is 
added for stabilization. 
3
rd
 GENERATION RECOMBINANT FACTOR VIII 
These have no added albumin or added protein at the end of preparation. 
LONGER HALF LIFE PREPARATIONS 
Factor VIII with longer half-life is desirable as it would decrease the 
frequency of dosing intervals in Haemophilia patients.  
 The two strategies under study for prolonging the half-life of factor VIII 
are – fusion with the Fc portion of immunoglobulin. 
 Reconstitution with pegylated liposomes 
 
INVESTIGATIONAL STRATEGIES 
A potentially exciting advance is to develop a product that would bind 
both Factor X and IXa, thereby bringing the two substrates together and 
bypassing the cofactor function of Factor VIII. This interesting idea is still 
under study. 
The choice of product depends on the purity, safety and cost. Purity and 
viral safety are utmost important to both, the treating physician and the patient. 
Ultrapure products are preferred in HIV coinfected Haemophiliacs as they 
stabilize the CD4 counts. 
 
46 
 
FACTOR IX PRODUCTS 
In the 1970s and 80s, Prothrombin complex concentrate was used. It was 
produced by the co-purification of Vitamin K dependant cofactors. This co-
purification resulted in the activation of Factor VII to VIIa resulting in an 
increase in thrombotic complications. PCCs are no longer preferred because of 
the increased thrombosis risk. Instead, purified human derived or recombinant 
factors are used. 
PURIFIED FACTOR IX 
Chromatographic partitioning and monoclonal antibody affinity 
purification are the techniques used to purify Factor IX. They are further 
subjected to viral inactivation processes. 
RECOMBINANT  FACTOR IX 
It is genetically engineered by inserting the gene for factor IX into a 
Chinese hamster ovary cell line. It has no added albumin and is safe in the 
treatment of patients with previously treated and untreated Haemophilia B. 
Half-life of recombinant factor is about 16 to 17 hours. 
LONGER ACTING PRODUCTS 
Factor with longer half-life are preferred as it would reduce the dosing 
intervals. As with Factor VIII, binding of factor IX to Fc portion of 
immunoglobulin increases the half-life about 3 to 5 fold. There are other studies 
investigating the use of Factor IX fused to Pegylated liposomes or albumin. 
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DOSING 
Early treatment of bleeding episodes with appropriate dose of factor will 
reduce the duration of bleed and prevent further complications. It also reduced 
the tendency to re-bleed. 
Several plasma products are available for raising factor levels. The major 
disadvantage of plasma is that large volumes need to be infused for maintaining 
very low factor levels. It is very difficult to achieve haemostasis with plasma 
infusion. Cryoprecipitate can be used. It contains 80 units of factor in 10ml. The 
disadvantages are the dosing of factor VIII can only be estimated and the 
cryoprecipitate has to be stored in a frozen state. 
In case of Haemophilia B, in older days, PCC was used. PCC contains 
vitamin K dependant factors including protein C and protein S. A few of the 
factors like VII IX and X become activated and increased incidence of 
thrombotic events has been reported including DIC. 
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To achieve 100% factor level, that is, 1u/ml, 3500 units of factor VIII is 
required. However, the site and the severity of bleed determines the dosing in a 
particular patient. Factor VIII can be given as infusion. After a loading dose, 
about 150 to 200 units per hour can be given as infusion. Factor levels can be 
monitored regularly using venous sampling
[40]
. 
The dose calculation for factor IX is different from that of Factor VIII as 
the intravascular recovery of factor IX is only 50%. This is probably due to the 
binding of Factor IX to collagen type IV in the vessel wall. The dose of factor 
IX can be estimated by assuming that 1 U of factor IX per kilogram body 
weight increases circulating factor IX by 1 per cent of normal or 0.01 U/ml. 
Thus, to achieve 100 percentage of normal (using only highly purified factor IX 
products) in a severely affected patient, 100 U of factor IX per kilogram body 
weight should be given as a bolus, followed by half this amount every 12 to 18 
hours. 
Prophylactic therapy can be attempted in Haemophilia B and the dosing 
is 20 to 40 units/kg twice a week
[39]
. 
HAEMOPHILIA A AND INHIBITORS 
The most important complication of Haemophilia is the development of 
inhibitors against factor VIII. 
Risk Factors 
1. Disease severity  
2. Exposure to factor concentrates  
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3. Method of purification of Factor VIII concentrates 
4. Genetic factors 
 
The inhibitors against factor VIII are antibodies that belong to the IgG4 
subclass. Most commonly these antibodies are directed against the A2 and C 
domain of Factor VIII. Early diagnosis of factor VIII inhibitors is important. 
The diagnosis is most often made when a patient does not respond to Factor 
VIII infusions. The inhibitors are detected using a common assay called the 
Bethesda assay. A mild modification of this is the Nijmegen assay. 
HIGH RESPONDERS 
High responders are defined as patients whose inhibitor titre is higher 
than 10 Bethesda units (BU) at baseline or whose initial inhibitor titre is less 
than 10 BU but rises to greater than 10 BU after administration of factor VIII
[32]
. 
Major bleeding episodes in high responders with initial inhibitor levels 
<10BU can be treated with high doses of either human factor VIII or porcine 
Factor VIII. This high will overcome the inhibitors. Though factor eight bypass 
activity can be used, it is not as reliable as factor VIII and the effects cannot be 
monitored by a reliable blood investigation. 
In major bleeds factor VIII is given in a dose of 10,000 to 15,000 units 
stat followed by 1000 units per hour infusion with frequent monitoring of factor 
VIII levels
[32][35]
. 
50 
 
In high responders with inhibitor less than 10BU, who experience minor 
bleeds, the preferred treatment would be factor eight inhibitor bypass activity or 
Recombinant factor VIIa. The dose of Recombinant factor VIIa is 90 to 
120mcg/kg that can be repeated at two to three hour intervals
[35]
. 
Patients with inhibitors >10BU rarely respond to high levels of factor 
VIII. In this case the treatment of choice would be either recombinant factor 
VIIa or factor VIII inhibitor bypass activity for both minor and major bleeds. 
LOW RESPONDERS 
Low-responder patients are arbitrarily defined as patients whose inhibitor 
titre is less than 10 BU even after challenge with factor VIII. For major bleeds 
high dose of factor VIII is recommended. In case of minor bleed, recombinant 
factor VIIa or FEIBA is preferred as most low responders become high 
responders when challenged with repeated doses of factor VIII
[35]
. 
IMMUNE TOLERANCE INDUCTION 
The most promising approach to the eradication of inhibitors is the 
immune tolerance induction. This involves the daily expose of these patients to 
factor VIII. Both low dose and high dose regimens have been tried. Bleeds that 
happen during the immune tolerance period are treated with factor VIII inhibitor 
bypass activity
[1][32]
. 
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Other immunosuppressive drugs, including cyclosporine and rituximab 
have been tried to eradicate the factor VIII inhibitors. However, these seem 
more promising in cases of acquired antibodies, in which case the antibodies are 
autoantibodies rather than alloantibodies as seen in Haemophilia patients. 
 
OTHER TREATMENT OPTIONS IN HEMOPIHLIA A 
DESMOPRESSIN 
Desmopressin is effective in mild to moderate haemophilia. Severe 
Haemophiliacs do not respond. The dose is 0.3mcg/kg body weight and the 
factor level increases 30 to 60 min after infusion. A concentrated nasal spray 
can be used at a dose of 150mcg in each nostril
[26]
. Tachyphylaxis can happen 
with repeated administration of desmopressin. 
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ANTIFIBRINOLYTIC THERAPY 
Anti-fibrinolytics like epsilon aminocaproic acid and tranexamic acid can 
be used as adjuvant in cases of mucosal bleeds. They are contraindicated in the 
presence of haematuria. The dose of EACA is 4 to 5gms stat followed by 
1gm/hr. Tranexamic acid can be given as 1g every fourth hourly
 [26][1]
. 
FIBRIN GLUE 
Fibrin glue is also known as fibrin tissue adhesive. It contains a mixture 
of fibrinogen, thrombin and factor XIII and can be applied topically to the 
injury site. It is most commonly used as an adjunctive to dental procedures. 
LIVER TRANSPLANTATION AND GENE THERAPY 
Liver transplantation has been done successfully in patients with 
Haemophilia and has resulted in complete cure in haemophilic patients. Gene 
therapy is under study and so far the results have been poor with the level of 
factor rise being very less and the level remained elevated only for a month. 
FACTOR IX AND INHIBITORS 
When the inhibitor titre is less than 10BU, it can be overcome with high 
doses of factor IX. In case of acute bleeds in patients with inhibitor levels 5 to10 
BU/ml should be treated with same factors used to bypass the activity of factor 
VIII inhibitor. Recombinant factor VIIa can be used in the dose of 90 to120 
mcg/kg ever 2 to 3 hrs
[26]
. Induction of immune tolerance can be tried with daily 
dosing of purified factor IX. 
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MATERIALS AND METHODS 
This study was done at Government Royapettah Hospital, Chennai for a 
period of eight months from December 2014 to September 2015. The study was 
performed after procuring informed written consent from all the participants 
involved. Clearance was obtained from the Ethical Committee of the 
Government Kilpauk Medical College & Hospital Chennai. 
STUDY DESIGN 
The study design is a cross sectional study. 
POPULATION 
The study population included 58 patients who attended the Haemophilia 
OP at Government Royapettah Hospital and in-patients in the same hospital. 
INCLUSION CRITERIA 
1. Patients diagnosed as Haemophilia including 
2. Factor VIII deficiency including inhibitors 
3. Factor IX deficiency 
4. Von Willebrand disease 
EXCLUSION CRITERIA 
1. New born babies with haemophilia  
2. Patients with acute bleed 
3. Bleeding disorders other than haemophilia  
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METHODOLOGY 
All patients, diagnosed and registered in the Haemophilia clinic were 
taken as the study population. The sample size was set to be 58.  
A detailed history regarding the onset and progression of the disease, 
family history, maternal carrier status, treatment history and the presence of 
complications were taken. 
After obtaining consent joint status assessment was done using 
Functional Independence Scoring in Haemophiliacs (FISH) scoring system. 
The observations were statistically analysed using SPSS 20.0 software and 
results were interpreted. 
 
 FUNCTIONAL INDEPENDENCE SCORE IN HEMOPHILIA (FISH)
[2] 
The Functional Independence Score in haemophilia (FISH) is a 
performance-based assessment tool to objectively measure an individual’s 
functional ability. It is intended to measure what the person with 
disability actually does. It can also be used to evaluate change in functional 
independence over time. It is relatively safe to perform this test.  
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The advantage is that it can be used with persons of different linguistic 
abilities, as it is an objective, performance-based instrument. It includes the 
assessment of 8 activities: eating, grooming, dressing, chair transfer, squatting, 
walking, step climbing, and running.  Each activity is graded according to the 
amount of assistance required to perform it.  
 
LEVELS OF FUNCTION AND THEIR SCORES 
4-  The subject is able to perform the activity without any  difficulty.  
3-  The subject is able to perform the activity without aids  or assistance, but  
with slight discomfort.  
2-  The subject needs partial assistance/ aids/ modified instruments/ modified 
environment to perform the activity. 
1- The subject is unable to perform the activity, or needs complete 
assistance. 
 
EATING AND GROOMING 
(A) EATING 
This activity assesses the subject’s ability to gather food from the plate 
and take it to the mouth. Important  aspects observed in this activity was 
posture, elbow movement,  cascade grasp (if using hands to eat) and the use of 
aids and adaptations.  
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Score 4  
 Has no difficulty in performing the activity. 
Score 3  
 Has to lean over unnaturally to reach his food due to limitation of 
flexion of the elbow. 
 Has to take several breaks in between due to pain. The subject is not to 
be asked if he has pain, but is to be observed to see if he has any 
discomfort. 
 Has no difficulty in performing the activity with prosthesis, using 
implements commonly used in his community. 
Score 2  
 Uses implements that are not commonly used in his community e.g. 
spoon or a fork in a community where other members use their hands. 
 Uses modified utensils/implements to feed himself. 
 Has difficulty feeding him using prosthesis, or uses implements that 
are not commonly used in his community. 
 Is a right-handed individual, but has to eat with his left hand due to 
problems with the right upper limb. 
Score 1   
 Is unable to feed himself. 
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(B) GROOMING 
Grooming includes oral care, hair grooming, washing hands and face. It 
does not include the subject’s ability to sit on the stool / floor / the surface on 
which the individual does the grooming. 
Score 4  
 The subject has no difficult in grooming. 
 The child needs assistance only to apply the toothpaste on the brush. 
Score 3  
 Adopts abnormal postures to comb the back of his head/ shave/ wash his 
face. 
 Experiences pain or discomfort while grooming (as assessed by the 
observer). 
 Takes an unnaturally long time to perform the activity. 
Score 2  
 Is not able to comb hair in all areas of the head -the back /side of the head  
 Requires any modified instrument. 
 Is a right-handed individual, but  uses  the left hand for grooming, due to 
problems with the right upper limb 
Score 1  
 Is unable to do the activity because of problems with reach. 
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BATHING 
This activity assesses the ability to wash, soap, and dry different parts of 
the body – including the perianal region, and feet. It is essential to assess the 
reach on both sides of the body, using both hands. 
Score 4  
 Has no difficulty in bathing. 
Score 3 
 Adopts unusual postures while bathing e.g. Places feet on a stool to 
apply soap. 
 is in discomfort while performing the activity 
Score 2  
 The subject requires a shower instead of water from a bucket in a 
community where the other members use water from a bucket 
(modified environment); but if others in the community too use the 
shower, score 4. 
 The bathtub or bathroom has to be modified (modified environment.) 
 The subject sits on a stool for his bath (modified environment.) 
 The subject has to use instruments to reach any part of the body 
(except the back). 
 The subject requires occasional help to bathe and dry the feet, 
perineum, or any other part of the body, except the back. 
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Score 1  
 The subject requires a bed bath, or is unable to perform most of the 
activity of bathing/ drying.  
DRESSING 
This activity assesses the ability to get dressed - wearing a shirt /T-shirt/ 
vest/ trouser/ dhoti /. This activity does not include ironing clothes or taking 
clothes from a cupboard. 
Score 4  
 Is able to get dressed without discomfort and without assistance. 
Score 3 
 experiences discomfort during the activity 
 Takes momentary support from the wall/ table to steady him while 
donning his trousers. 
 Uses adaptive manoeuvres to don the shirt due to discomfort. 
Score 2  
 Requires help to wear the trouser. 
 Sits to put on his trousers (aid). 
 Requires considerable amount of support from the wall/ table while 
donning trousers. 
 Requires complete help in <50% of the activity, e.g. – partial 
assistance in donning the trouser, but no help required in putting on 
the shirt.  
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Score 1  
 Requires help in >50% of the activity. 
CHAIR TRANSFER 
Chair with armrests of an appropriate height was placed in front of the 
subject. The subject was asked to oppose his palms, get up from  the chair,  and 
then sit down. 
Score 4  
 Has no difficulty in performing the above activity. 
Score 3  
 Leans excessively forward in order to get up. 
 Sits with one or both knee joints slightly extended, but does not require 
support to get up. 
 uses  momentary support of the arm  rest while getting up 
Score 2 
 Requires a lot of support from the armrest to get up. 
 Requires the use of crutches to get up. 
Score 1  
 Is not able to get up from the chair. 
SQUATTING 
This assesses the ability to squat on the floor and rise to an erect posture. 
The subject was asked to stand by the wall ,and  to oppose his palms (as in a 
prayer/ Namaste position).  
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This is a provocative test. Hence we asked the patient first, if he feels able 
to perform the activity. If they said it is not possible for them  to squat,  the test 
was stopped, and the subject scored appropriately. 
Score 4  
 Has no difficulty in performing the activity. 
Score 3  
 Is able to squat to a height of 8-12 inches (6-10 for children). 
 Is able to squat to a height of 8 inches, with one leg in extension 
(6inches for children). 
 Is able to squat to a height of 8-12 inches (6-10 for children) using 
momentary support from  the side/floor 
Score 2 
 Is able to squat to a height of 8-12 inches (6-10 for children) with 
maximum support from a chair/grab-rail. 
Score 1 
 is not able to squat to a height of 12 inches with support from  the side   
WALKING PATTERN 
Walking was assessed over a distance of 10 meters.  There has to be a 
good heel to toe pattern in the gait, with steps of relatively equal length and 
cadence. Heel strike should be with knee in full extension. The knee should 
bend adequately during stance and swing phase. There should not be an obvious 
limp. 
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Score 4  
 Has an apparently normal gait. 
Score 3 
 Has a stiff knee gait/ limp. If stance phase in a limb is reduced due  to 
pain  
Score 2  
 Uses a cane/walking stick. 
 Uses a knee/ankle brace 
Score 1  
 Is unable to walk 10 meters. 
STAIR CLIMBING 
The subject was placed in front of a flight of stairs side rails and asked to 
climb at least 14 steps, each of approximately 8 inches in height. This is a 
provocative test therefore subjects were not forced to perform. If they felt they 
are not able to do, scoring was given accordingly 
 
Score 4  
 Is able to climb up/down the stairs without a limp or aid with an 
alternating stepping pattern. He should be able to climb up/down the 
steps in less than 9 seconds . 
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Score 3  
 Has a limp/discomfort while climbing the steps. If he uses the rails for 
occasional minimal support – he should be able to climb up/down the 
steps within 14 seconds (in either direction). 
 Climbs up or down the stairs, taking one step at a time. 
Score 2  
 Takes more than 14 seconds to climb up/down the stairs using the aid 
of the rails or crutches/ assistance of a helper (in either direction). 
Score 1  
 Is unable to climb 14 steps. 
RUNNING 
Running was assessed over a distance of 25 meters for children, and 50 
meters for adults. Subjects were not forced to perform this provocative test. 
Score 4  
 Has no difficulty/discomfort while running. 
Score 3  
 Has pain/discomfort while running. 
 Is able to run only part of the distance. 
Score 2 
 is not able to run, but is able to walk briskly  
Score 1  
 is not able to walk briskly  
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DESCRIPTIVE STATISTICS FOR FISH SCORE 
TABLE 1 
FISH MINIMUM MAXIMUM MEAN 
STD. 
DEVIATION 
Eating/grooming 1 4 3.88 0.462 
Bathing 1 4 3.59 0.838 
Dressing 1 4 3.59 0.838 
Chair 1 4 3.47 1.012 
Squatting 1 4 2.71 1.257 
Walking 1 4 3.34 0.983 
Stairs 1 4 2.97 1.108 
Running 1 4 2.60 1.363 
Total fish score 8 32 26.00 6.551 
 
Lowest mean score was for squatting, running and then stair climbing 
Mean FISH score was 26, lowest was 8 and maximum of 32. 
AGE DISTRIBUTION 
TABLE 2 
PARAMETER N MINIMUM MAXIMUM MEAN S.D 
Age in years 58 4 85 28.24 16.770 
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From the analysis the minimum age of the study population was 4years 
and maximum age was 85, with a mean age of 28.24. 
 
AGE OF DIAGNOSIS OF DISEASE 
TABLE 3 
MINIMUM MAXIMUM MEAN S.D 
0 38 5.50 8.844 
  
Minimum age of diagnosis was at birth and the maximum age was 38 
years, with a mean age of 5.5 years. 
 
TABLE 4 
 
From this table it is pointed out that, there is a significant negative 
correlation between age and duration of disease and FISH score, i.e., as the age 
and duration of disease increases, the FISH score is reduced. 
 
 
 
FISH Age in years 
Duration of 
disease(yrs) 
Total fish score -.678(**) -.562(**) 
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GENDER 
 
TABLE 5 
SEX FREQUENCY PERCENT 
Male 54 93.1 
Female 4 6.9 
 
 
                             
Majority – 93% of the study population were males, as it is an X linked 
disorder. 7 % were females and these patients had Von Willebrand disease. 
 
 
 
 
 
 
93% 
7% 
GENDER DISTRIBUTION 
Male Female
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DISEASE (HEMOPHILIA) 
TABLE 6 
DISEASE (HEMOPHILIA) FREQUENCY PERCENT 
A 44 75.9 
B 10 17.2 
Von Willebrand 4 6.9 
                                           
75% are hemophilia A patients. 17% are hemophilia B and only 7% von 
willebrand disease. 
 
TABLE 7 
FISH DISEASE N MEAN S.D P VALUE 
Total fish 
score 
A 44 25.95
 
6.390 
0.183 
B 10 24.10
 
7.724 
Von 
Willebrand 
4 31.25
 
1.500 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
Type of disease did not significantly influence the FISH score. 
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SEVERITY 
TABLE 8 
SEVERITY FREQUENCY PERCENT 
Mild 7 12.1 
Moderate 10 17.2 
Severe 41 70.7 
                 
                  
Majority -71% of them are severe hemophiliacs. 17% belong to mild and 
moderate group. 
TABLE 9 
FISH SEVERITY N MEAN 
STD. 
DEVIATION 
P 
VALUE 
Total fish 
score 
Mild 7 24.86
 
9.155 
0.195 Moderate 10 29.40
 
3.688 
Severe 41 25.37
 
6.480 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
Severity of the disease did not significantly alter the FISH score. 
12% 
17% 
71% 
DISEASE SEVERITY 
Mild Moderate Severe
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INHIBITOR STATUS 
TABLE 10 
INHIBITOR FREQUENCY PERCENT 
Positive 4 6.9 
Negative 54 93.1 
            
 
 
                  
 7% are inhibitor positive.  94% are negative for inhibitor status. 
 
TABLE 11 
FISH 
INHIBITOR 
STATUS 
N MEAN 
STD. 
DEVIATION 
P 
VALUE 
Total fish 
score 
Positive 4 20.75 9.845 
0.097 
Negative 54 26.39 6.199 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
Total FISH score was not significantly affected by inhibitor status. 
 
0 20 40 60 80 100
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6.9 
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EDUCATIONAL QUALIFICATION 
TABLE 12 
 EDUCATIONAL 
QUALIFICATION 
FREQUENCY PERCENT 
Primary 11 19 
High School 24 41.4 
Graduate 23 39.7 
 
 
 
This table shows majority of the population had high school education or 
graduates.19% stopped with primary school. 
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OCCUPATION 
 
TABLE 13 
OCCUPATION FREQUENCY PERCENT 
Unemployed 7 12.1 
Student 21 36.2 
Semi skilled 19 32.8 
Unskilled 6 10.3 
Professional 5 8.6 
 
 
 
  
Most of the patients were students, followed by semi skilled workers. 
12% patients were unemployed. 
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TABLE 14 
EMPLOYMENT 
STATUS 
N MEAN 
STD. 
DEVIATION 
P Value 
Unemployed
a 
7 18.14 7.988 
<0.01** 
Student
c 
21 31.76 .625 
Semi skilled
a 
19 22.11 5.065 
Unskilled
b 
6 26.50 5.505 
Professional
b 
5 27.00 2.121 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
 
 
Mean FISH score was lowest in unemployed group and highest in 
students at level 1 significance using ANOVA and POST HOC DUNCAN 
TESTS. 
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IQ 
TABLE 15 
IQ FREQUENCY PERCENT 
Normal 52 89.7 
Sub Normal 6 10.3 
Total 58 100 
 
                   
90% patients were having normal IQ and 10% were having sub normal IQ. 
TABLE 16 
FISH IQ N MEAN S.D 
P 
VALUE 
Total 
fish 
score 
Normal 52 26.58 5.886 
0.047* Sub 
Normal 6 21 10.119 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
 
From this table, FISH scoring was significantly low (level 5) in patients with 
sub normal IQ. 
 
90% 
10% 
IQ LEVEL 
Normal Sub Normal
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MONTHLY INCOME(RS) 
TABLE 17 
MONTHLY 
INCOME(RS) 
FREQUENCY PERCENT 
No income 28 48.3 
Below 10000 15 25.9 
10000-20000 10 17.2 
Above 20000 5 8.6 
 
48% patients are in the no income group. Only 9% are in the high income 
group. 
TABLE 18 
INCOME 
GROUP 
N MEAN S.D P VALUE 
No income
b 
28 28.36
b 
7.109 
0.018* 
Below 10000
ab 
15 25.73
ab 
3.845 
10000-20000
a 
10 22.10
a 
5.685 
Above 20000
a 
5 21.40
a 
6.504 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
 
Total fish score was significantly (level 5) low in high income groups 
compared to others using ANOVA and POST HOC DUNCAN TESTS. 
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FREQUENTLY INVOLVED JOINT 
TABLE 19 
JOINT FREQUENCY 
knee 26 
elbow 16 
ankle 6 
hip 2 
shoulder 1 
  
 
  
Majority of patients had knee joint involvement, followed by elbow and 
ankle joints. 
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JOINT DISEASE 
TABLE 20 
TYPE FREQUENCY PERCENT 
Single 8 13.7 
Multi 50 86.2 
 
 
 
86% of patients had multi joint disease, i.e., arthropathy involving 
more than one joint.The arthropathy occurs due to iron deposition and fibrosis 
of the synovium. Repeated hemarthrosis can accelerate the arthropathy process 
thereby affecting the patients’ quality of life. 
 
SINGLE VS MULTI JOINT DISEASE 
FISH SCORE was significantly lower (level 5) in patients with MULTI 
JOINT DISEASE. 
FISH SCORE was significantly lower (level 5) in patients with MULTI 
JOINT DISEASE using TWO TAILED T TEST. 
14% 
86% 
TYPE OF JOINT DISEASE 
Single Multi
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TABLE 21 
JOINT 
DISEASE 
N MEAN S.D P VALUE 
Single 8 30.13 3.834 
0.027* 
Multi 45 24.60 6.638 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
 
AVERAGE BLEED 
TABLE 22 
PARAMETER MIN MAX MEAN S.D 
Avg. Bleed per month 0 6 1.41 1.364 
Avg. Bleed per year 0 150 15.84 21.683 
 
Maximum bleed per month was 6 with a mean of 1.4 episodes. Mean 
bleed per year per patient was 16 episodes. 
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CO MORBIDITIES 
 
TABLE 23 
CO MORBIDITIES FREQUENCY PERCENT 
Present 7 12.1 
Absent 51 87.9 
 
12% of hemophiliacs had co morbidities like HIV, HBSAG, diabetes or 
hypertension. 
TABLE 24 
CO MORBID N MEAN S.D P VALUE 
Present 7 19.00 7.616 
0.002** 
Absent 51 26.96 5.845 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
 
FISH score was significantly lower in patients with co morbidities like 
HIV/HBSAG assessed using TWO TAILED T TEST. 
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SURGERY 
TABLE 25 
SURGERY FREQUENCY PERCENT 
Yes 17 29.3 
No 41 70.7 
 
29% Patients had previous surgical history. 
 
USING ORTHOTICS 
TABLE 26 
USING ORTHOTICS FREQUENCY PERCENT 
Yes 12 20.7 
No 46 79.3 
 
 
 
20% of the study population are using orthotics for support and walking. 
 
 
21% 
79% 
ORTHOTICS 
Yes No
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TABLE 27 
FISH 
Using 
orthotics 
N Mean 
Std. 
Deviation 
P 
VALUE 
Total fish 
score 
Yes 12 16.50 5.334 
<0.01** 
No 46 28.48 4.130 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
FISH score was significantly low in patients using orthotic support. 
PROPHYLAXIS 
TABLE 28 
PROPHYLAXIS FREQUENCY PERCENT 
Yes 2 3.4 
No 56 96.6 
Majority of our patients are not on prophylaxis treatment. Only 2 patients 
are using prophylactic factor administration. 
 
TABLE 29 
PROPHYLAXIS N MEAN 
STD. 
DEVIATION P VALUE 
Yes 2 26.00 1.414 
1.000 
No 56 26.00 6.666 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
Prophylaxis use did not significantly affect fish score probably because 
less no. Of patients were under prophylaxis 
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PHYSIOTHERAPY 
TABLE 30 
PHYSIOTHERAPY FREQUENCY PERCENT 
Never 13 22.4 
Occasion 10 17.2 
Regular 35 60.3 
 
 
60% are doing regualr physiotherapy, and the remaining are occasionally 
doing or never done physiotherapy. 
TABLE 31 
FISH PHYSIO N Mean S.D P VALUE 
Total fish 
score 
Never 13 29.46
 
6.319 
0.073 Occasion 10 26.30
 
7.646 
Regular 35 24.63
 
5.986 
 
Regular physiotherapy is not significantly improving FISH score. 
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MODE OF TRANSPORT 
TABLE 32 
MODE OF RANSPORT FREQUENCY PERCENT 
Public 24 41.4 
Private 34 58.6 
 
 
58 % are using their own transport for medical treatment, and the 
remaining are using public transport like BUS and TRAIN for treatment. 
TABLE 33 
Mode of 
transport(vehicle) 
N Mean Std. Deviation P VALUE 
Public 24 25.38 6.819 
0.546 
Private 34 26.44 6.421 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
Mode of transportation for treatment did not significantly affect FISH scoring 
 
Public, 41.4 
Private, 58.6 
TYPE OF TRANSPORT 
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DISTANCE TRAVELLED FOR TREATMENT 
TABLE 34 
MINIMUM MAXIMUM MEAN S.D 
1 300 33.50 63.710 
 
 
Minimum distance travelled for treatment is 1km and a maximum was 
300km, with a mean distance of 33.50 km. 
 
TABLE 35 
FISH DISTANCE  N Mean S.D P VALUE 
Total fish 
score 
Below 10 20 24.30 7.706 
0.358 11-20 24 27.04 5.737 
Above 20 14 26.64 6.021 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
 
Distance travelled did not significantly influence FISH score 
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COST OF TREATMENT 
TABLE 36 
COST  FREQUENCY PERCENT 
Free 47 81 
Subsidised 10 17.2 
Paid 1 1.7 
 
 
TABLE 37 
COST N Mean S.D P VALUE 
Free 47 26.40 6.024 
0.122 Subsidised 10 25.40 8.140 
Paid 1 13.00 . 
** imply Significant at 1 level (Highly Significant ) 
* imply Significant at 5 level (Significant ) 
 No star imply no statistical significance
 
Type of treatment did not significantly influence FISH scoring 
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DISCUSSION 
Analysis of FISH score shows that lowest scores are for squatting , 
followed by running and stair climbing. Mean FISH score was 26, the results 
are comparable to a Mexican study done by Alberto Tlacuilo et al
[45]
, where the 
mean FISH of Mexican haemophiliacs was 25.8. Since squatting was most 
difficult to perform, we should give early toilet training to haemophilia children 
and advice them to use western style lavatories to avoid stress on knee joint.    
Demographic and clinical characteristics of our study population are, 
Oldest patient was 85 years and the mean age of study population was 28 years, 
whereas a similar study conducted by A.kar et al in Kolkata haemophilia 
society, INDIA had a mean age of to be 19.2 years.
[ 44]
. 
Mean age of diagnosing haemophilia in our centre was 5.5 years, which 
was comparatively late than western population
[47]
. Age also seems to be an 
important factor in determining joint function, as we can see, as the age goes up, 
the FISH score becomes significantly lower. 
Tables 5 and 6 shows that 93% were males , this group majority were 
hemohilia A and 7 % were females. All females had von willebrand disease. 
But the type of disease did not significantly influence joint function. 
70% of our patients are having severe disease i.e., factor levels <1%, but 
the severity of their disease did not affect the joint function, probably because 
arthropathy is a chronic problem due to repeated joint trauma, rather than the 
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factor levels in the serum.7% were inhibitor positive but it did not significantly 
affect the FISH score. 
All our patients had basic primary education, and none of them were 
uneducated. But 19% patients stopped with primary school and 40% with high 
school, whereas 40% were graduates. 
Tables 13 and 14 shows that majority of our study population were 
students or employed as per their educational standards, only 12% were 
unemployed. 
Table 17 shows that 48% population were in the no income group , 
probably because most of our patients were students , hence they did not have 
stable income source, comparable to a similar study in Kolkata
[44]
. 
Our study had 10% patients with sub normal I Q levels, and they were 
significantly having low FISH score, which shows that I Q is an important 
determinant of joint health. 
Most commonly involved joint in our study was knee joint followed by 
elbow and ankle joints similar to Buzzard et al
[48]
, because these joints lack 
edequate muscle cover and are not able to withstand rotatory and angular stress. 
We also found that 86% of our patients had multi joint disease i.e., arthropathy 
of more than one joint and it significantly lowered their FISH score. 
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Mean bleeding episodes is 16 episodes per year. We expected that as the 
bleeding episodes increase FISH score to come down but in our study the result 
was not significant. 
7 patients had associated HIV or HBSAG infection and these patients had 
significantly lower Functional status compared to the rest of the population. 
20 % of the population are using orthotic support and their FISH score was 
significantly low compared to others. 
Only 2 of patients were on prophylaxis treatment compared to the 
western population where majority of severe haemophiliacs take prophylaxis
 
[47]
, these western studies have shown that prophylactic treatment prevents 
hemophilic arthropathy 
48% of patients were on regular physiotherapy but that did no 
significantly improve their FISH score, this result was similar to A.Kar et al
[44]
, 
which may be because the patients were doing exercise to reduce the effect of 
impairment rather than for strengthening their joints. More studies are required 
to probe into what type of exercise the patients are actually doing. 
Our patients travelled upto maximum 300km for treatment and mean was 
33km and most used their own vehicle for coming to hospital. Their travel was 
not significantly affecting the FISH score. In the study conducted by A.Kar et al 
in Kolkata
[44]
 where they compared cost of treatment with disability was also 
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significant. Opening of more treatment centres and starting home based self-
administration of factors would help patients to avoid long travel for treatment.  
Table 36 shows that more than 80% of the haemophilia patients are 
taking free treatment from the state, which is a good indicator how health care 
has improved in the state of Tamil Nadu.  
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CONCLUSION 
 In this study we have documented the widespread prevalence of 
haemophilic arthropathy, which is a preventable disability. 
  The study explored the risk factors for disability with the objective of 
identifying some modifiable risk factors that could be used in future. 
 Traditionally joint status is measure using radiological and clinical scores 
measuring range of movement of individual joints, but these scores 
involves exposure to radiation, cumbersome use of goniometer yet do not 
adequately assess the functional ability of patients. Hence we have used 
FISH scoring system, which is a reliable, inexpensive and easily 
administered even by paramedical workers and takes only 12 minutes per 
patient.  
 Patients can also be followed up to see if their functional status comes 
down over a period of time. 
 Squatting was the most affected movement in our patients. 
 Most of the patients travelled a long distance for treatment, therefore 
opening of more treatment centres and home therapy may be sought for. 
 Majority of our patients are taking on demand treatment. Global studies 
have shown that prophylactic treatment has reduced the incidence of 
chronic arthropathy. More Indian studies are needed in this aspect to see 
the impact on Indian population. 
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LIMITATIONS OF THE STUDY 
The test used some provocative movements which could not be done by 
some patients. Only the functional limitations of our patients were assessed but 
this could not identify early arthropathy changes, where functions are not 
limited. Larger multicentre trials with more number of subjects are required. 
The functional assessment should be coupled with radiological and goniometric 
measurement for better joint status assessment. 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
 BIBLIOGRAPHY 
 
1. Hoffman text book of haematology 
2. Poonnoose PM, Thomas R, Bhattacharjee S, Shyamkumar NK, 
Manigandan C, Srivastava A. Functional Independence Score in 
Haemophilia (FISH): A new performance based instrument to measure 
disability. Haemophilia 2005; 11:598-602. 
3. Morawitz P: Die Chemie der Blutgerinnung. Ergeb Physiol 4:307, 1905 
4. Pavlovsky A: Contribution to the pathogenesis of hemophilia. Blood 
2:185, 1947 
5. Brinkhous KM: A study of the clotting defect in hemophilia. The 
delayed formation of thrombin. Am J Med Sci 198:509, 1939 
6. Williams text book of haematology 
7. Epidemiology and social costs of haemophilia in India review article                       
J MED RES July 2014 
8.  Clinical features and manifestations of Haemophilia A – up-to-date 
9. A ten years cohort study. J Assoc Physicians India 2005; 53 :1021-
Mohanty D, Colah RB, Gorakshakar AC, Patel RZ, Master 117 
10. DC, Mahanta J, et al. Prevalence of β-thalassemia and other 
haemoglobinopathies in six cities in India: a multicentre study. J 
Community Genet 2013; 4 : 33-42. Chatterjee N, Mishra A, Soni R, 
Kulkarni H, Mamtani M,Shrivasatava M. Bayesian estimates of the 
prevalence of β-thalassemia trait in voluntary blood donors of central 
India: a survey. Hemoglobin 2010;34 : 548-60.Christianson A, Modell  
11. Medical genetics in developing countries. Annu Rev Genomics Hum 
Genet 2004; 5 : 219-65.Genome-based Research and Population Health. 
12. Report of an expert workshop held at the Rockefeller Foundation Study 
and Conference Centre; 2005 April 14-20; Bellagio, Italy. Available 
from: http://www.phgfoundation.org/file/2205, accessed on November 
22, 2012.  
13. UNICEFIndiastatistics.http://www.unicef.org/infobycountry/india_statis
tics.html, accessed on October 15, 2012.  
14. Census of India 2011, Office of the Registrar General and Census 
Commissioner, India, Controller of Publications, New Delhi. Available 
94 
 
from: http://www.censusindia.gov.in/2011-provresults/ 
prov_results_paper1_india.html, accessed on October 12, 2012. 
15.  http://www.censusindia.gov.in/2011-Common/srs.html,accessed on 
October 12, 2012. 
16. Rural Health Mission PIP: 2012-13 Mission Flexipool. Government of 
Maharashtra. Available from: 
http://www.nrhm.maharashtra.gov.in/partb.pdf, accessed on May 9, 
2013. 
17. Skinner MW. WFH: closing the global gap - achieving optimal 
care.Haemophilia 2012; (Suppl 4) : 1-12. Lee CA. Historical 
introduction. In: Lee C, Berntorp E, Hoots K, editors 
18.  Textbook of hemophilia. 2nd ed. West Sussex: Wiley-Blackwell;2010. 
p. 1-6. van den Berg HM, Fischer K.  
19. Phenotypic - genotypic relationship. In: Lee C, Berntorp E, Hoots K, 
editors. Textbook of hemophilia, 2nd ed. West Sussex: Wiley-
Blackwell; 2010. p. 33-7.Mannucci PM, Tuddenham EG.  
20. The hemophilias - from royal genes to gene therapy. N Engl J Med 
2001; 344: 1773-9. Bowen DJ.  
21. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 
2002; 55: 127-44. Berntorp E, Shapiro AD 
22. . Modern haemophilia care. Lancet 2012; 379 : 1447-56.Philipp C.  
23. The aging patient with hemophilia: complications, comorbidities, and 
management issues. Hematology Am Soc Hematol Educ Program 2010; 
2010 : 191-6. Cohen JS, Biesecker BB.  
24. Quality of life in rare genetic conditions: a systematic review of the 
literature. Am J Med Genet A 2010;152A : 1136-56. Dharmarajan S, 
Phadnis S, Gund P, Kar A.  
25. Out-of-pocket and catastrophic expenditure on treatment of haemophilia 
by Indian families. Haemophilia 2014; 20 : 382-7.Haldane JB.  
26. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM: The diagnosis 
and management of factor VIII and IX inhibitors: A guideline from the 
UK Haemophilia Centre Doctors' Organization (UKHCDO).  Br J 
Haematol  2000; 111:78. 
27. Gene deletions in patients with haemophilia B and anti-factor IX 
antibodies. Nature 1983; 303 : 181-2. World Federation of Haemophilia 
(WFH). 
95 
 
28. Kasper CK, Aledort L, Aronson D, et al: Proceedings: A more uniform 
measurement of factor VIII inhibitors.  Thromb Diath Haemorrh  1975; 
34:612. 
29. Dharmarajan S, Phadnis S, Gund P, Kar A. Treatment decisions and 
usage of clotting factor concentrate by a cohort of Indian haemophilia 
patients. Haemophilia 2012; 18 : e27-9.Haemophilia Federation (India). 
Available from: http://www.hemophilia.in/, accessed on October 12, 
2012. 
30. Gilbert MS: Musculoskeletal complications of haemophilia: The joint. 
Haemophilia 6:34, 2000. [PMID: 10982265] 
31. Hanley JP, Ludlam CA: Central and peripheral nervous system bleeding, 
in Hemophilia, edited by CD Forbes, L Aledort, R Madhok, p 87. 
Chapman & Hall, London, 1997. 
32. Astermark J, Oldenburg J, Escobar M, White 2nd GC, Berntorp E: The 
Malmo International Brother Study (MIBS). Genetic defects and 
inhibitor development in siblings with severe hemophilia A.  
Haematologica  2005; 90:924.. 
33. Gill F: The natural history of factor VIII inhibitors in patients with 
hemophilia A.   In: Hoyer LW, ed. Factor VIII Inhibitors: Proceedings 
of an International Symposium Held in Farmington, Connecticut,  
Berlin, Heidelberg: Springer; November 3–5, 1983:19.1984  
34. Steven MM, Yogarajah S, Madhok SD, et al: Hemophilic arthritis.  Q J 
Med  1986; 58:181 
35. Astermark J: Treatment of the bleeding inhibitor patient.  Semin Thromb 
Hemost  2003; 29:77..  
36. Joint range-of-motion limitations among young males with 
hemophilia:prevalence and risk factors J. Michael Soucie, Christy 
Cianfrini et al. 
37. Physical Functioning in Boys with Hemophilia in the U.S.Paul E. 
Monahan, MD, Judith R. et al. 
38. Kreuth III: European consensus proposals for treatment of haemophilia 
with coagulation factor concentrates P. GIANGRANDE, R. SEITZ et al. 
39. Guidelines for the management of haemophilia A. SRIVASTAVA,* A. 
K. BREWER et al. 
40. Factors affecting the Haemophilia Joint Health Score in children with 
severe haemophilia M. BLADEN, E. MAIN et al. 
96 
 
41. Motor performance and disability in Dutch children with haemophilia: a 
comparison with their healthy peers M. A. G. C. SCHOENMAKERS et 
al. 
42. Pain and functional limitations in patients with severe haemophilia F. R. 
VAN GENDEREN et al. 
43. Long-term major joint outcomes in young adults with haemophilia: 
interim data from the HGDS Y. SU, W.-Y. WONG et al. 
44. Disability in Indian patients with haemophilia A. KAR,* R. 
MIRKAZEMI et al. 
45. Functional Independence Score in haemophilia: A Cross-Sectional 
Study Assessment of Mexican Children Alberto Tlacuilo-Parra, MD, 
MSc, Justo Villela-Rodriguez et al. 
46. Guideline on the selection and use of therapeutic products to treat 
haemophilia and other hereditary bleeding disorders. 
47. Joint range-of-motion limitations among young males with haemophilia: 
prevalence and risk factors. Michael Soucie, Christy Cianfrini et al. 
48. Buzzard BM. Physiotherapy for prevention and treatment of chronic 
haemophilic synovitis. Clin Orthop Relat Res 1997; 343: 42–6. 
 
 
 
 
97 
 
 
 
ANNEXURES 
 
 
 
98 
 
 
99 
 
 
100 
 
PROFORMA 
 
NAME 
AGE 
SEX 
ADDRESS 
 
PHONE NO. 
EDUCATION 
GENERAL I.Q 
OCCUPATION 
      TYPE – PROFESSIONAL 
                   SEMI SKILLED 
                   UNSKILLED(MANUAL WORKER) 
SPECIAL SKILLS 
MONTHLY INCOME 
DISEASE  
SEVERITY 
AGE AT DIAGNOSIS 
YEARS LIVED WITH DISEASE  
TRANSIENT INHIBITOR 
BLOOD PRODUCT ADMINISTERED – YES/NO 
HOW MANY YEARS BLOOD PRODUCTS WERE TAKEN 
PURIFIED FACTOR ADMINITRETED SINCE WHEN 
INHIBITOR STATUS 
DURATION AS INHIBITOR 
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CO MORBIDITIES – DIABETES 
                              HYPERTENSION 
                              HIV 
                              HBSAG/HCV 
TYPE OF BLEEDS EXPERIENCED – JOINT 
                                                         MUSCLE 
                                                        MUCOSAL 
JOINTS FREQUENTLY INVOLVED  
SINGLE/MULTI JOINT DISEASE 
UNDERGONE ANY JOINT SURGERY – YES/NO 
USING ORTHOTICS FOR SUPPORT – YES/NO 
TAKING PROPHYLACTIC TREATMENT – YES/NO 
AVERAGE JOINT BLEED EXPERIENCED PER MONTH 
AVERAGE JOINT BLEED EXPERIENCED PER YEAR 
PHYSIOTHERAPY – DOING REGULARLY 
                                 DOING OCCASIONALY 
                                 NEVER DONE 
DISTANCE TRAVELLED FOR TREATMENT  
MODE OF TRANSPORTATION FOR TREATMENT 
TYPE OF TREATMENT – PAYING FULL COST 
                                          SUBSIDIZED TREATMENT 
                                          FREE OF COST 
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